What is the recommended dose of aztreonam (Aztreonam) for a patient with urosepsis and impaired renal function (creatinine clearance (CrCl) of 46)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Aztreonam Dosing for Urosepsis in Patient with CrCl of 46 mL/min

For a patient with urosepsis and a creatinine clearance of 46 mL/min, the recommended dose of aztreonam is 1-2 grams every 8-12 hours with no dose adjustment needed. 1

Dosing Recommendations Based on Renal Function

  • For patients with creatinine clearance between 30-50 mL/min, standard aztreonam dosing can be maintained as no adjustment is required 1
  • The FDA-approved dosing for urinary tract infections is 500 mg to 1 g every 8 or 12 hours, while for severe systemic infections like urosepsis, 1-2 g every 8 hours is recommended 1
  • Dose adjustments are only required when creatinine clearance falls below 30 mL/min 1, 2

Specific Dosing Algorithm for Urosepsis

  • For urosepsis (severe systemic infection), the recommended initial dose is 2 g every 8 hours due to the serious nature of infections involving Pseudomonas aeruginosa and other gram-negative pathogens 1, 3
  • For patients with creatinine clearance between 30-50 mL/min, no dose adjustment is needed as this is considered mild renal impairment 1, 4
  • Dosage should only be halved when creatinine clearance falls between 10-30 mL/min 1

Pharmacokinetic Considerations

  • Aztreonam is primarily eliminated through renal excretion with 60-70% of the drug excreted unchanged in urine 5
  • Population pharmacokinetic modeling supports adequate probability of target attainment (>90%) with standard dosing for patients with moderate renal impairment 4
  • For severe infections like urosepsis, maintaining adequate peak concentrations is critical for bactericidal activity against gram-negative pathogens 5, 6

Important Clinical Considerations

  • Aztreonam has excellent activity against aerobic gram-negative bacteria including Pseudomonas aeruginosa, which are common causative organisms in urosepsis 7, 3
  • For empiric treatment of urosepsis where the causative organism is unknown, consider combination therapy to cover gram-positive and anaerobic bacteria as aztreonam lacks activity against these organisms 3, 6
  • Duration of therapy should generally continue for at least 48 hours after the patient becomes asymptomatic or evidence of bacterial eradication has been obtained 1

Monitoring Recommendations

  • Monitor renal function during therapy as changes in creatinine clearance may necessitate dose adjustments if it falls below 30 mL/min 1, 2
  • For patients with fluctuating renal function, more frequent assessment of creatinine clearance may be needed to ensure appropriate dosing 2
  • Persistent infections may require treatment for several weeks; clinical response should guide duration of therapy 1

Common Pitfalls to Avoid

  • Avoid decreasing the dose rather than increasing the dosing interval in patients with severe renal impairment (CrCl <30 mL/min), as this may lead to subtherapeutic peak concentrations 2
  • Do not use doses smaller than indicated in the prescribing information as this may lead to treatment failure 1
  • Remember that for serious infections like urosepsis, the intravenous route is recommended over intramuscular administration 1

References

Guideline

Medication Dosing in Renal Impairment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

How and why aztreonam works.

Surgery, gynecology & obstetrics, 1990

Research

Aztreonam activity, pharmacology, and clinical uses.

The American journal of medicine, 1990

Research

Aztreonam: the first monobactam.

The Medical clinics of North America, 1988

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.